A Multicenter, Open-label, Phase III Study to Assess the Efficacy, Safety, and Pharmacokinetics of Macitentan in Japanese Pediatric Patients (≥3 Months to <15 Years) With Pulmonary Arterial Hypertension
Latest Information Update: 12 Jan 2025
Price :
$35 *
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 17 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 26 Apr 2022 Planned initiation date (estimated date of first participant enrollment) changed from 6 May 2022 to 29 Jun 2022.
- 26 Apr 2022 Planned initiation date changed from 6 May 2022 to 29 Jun 2022.